BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co CROIC

The Cash Return on Invested Capital (CROIC) of BrightGene Bio-Medical Technology Co (688166.SS) as of Oct 29, 2026 is -3.28 %. In the previous year, Cash Return on Invested Capital (CROIC) was -0.29 % — a change of 1,015.71% (lower).

CROIC

-3.28 %

YoY

1,015.71%

Last updated:

Cash Return on Invested Capital (CROIC) of BrightGene Bio-Medical Technology Co is 2025 -3.28 % . Cash Return on Invested Capital (CROIC) of BrightGene Bio-Medical Technology Co was 2024 -0.29 % . It decreases by 1,015.71% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-6.27 CNY
Jan 1, 2019
-2.15 CNY
Jan 1, 2020
-13.24 CNY
Jan 1, 2021
-31.94 CNY
Jan 1, 2022
-11.03 CNY
Jan 1, 2023
-4.88 CNY
Jan 1, 2024
-0.29 CNY
Jan 1, 2025
-3.28 CNY
The BrightGene Bio-Medical Technology Co CROIC history
YEARCROICYoY
-3.28 %+1,015.71%
-0.29 %-93.98%
-4.88 %-55.71%
-11.03 %-65.47%
-31.94 %+141.22%
-13.24 %+516.40%
-2.15 %-65.76%
-6.27 %-41.63%
-10.75 %+245.48%
-3.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Cash Return on Invested Capital (CROIC) of BrightGene Bio-Medical Technology Co is -3.28 % in 2025.

Cash Return on Invested Capital (CROIC) of BrightGene Bio-Medical Technology Co changed from -0.29 % to -3.28 %, representing a 1,015.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — BrightGene Bio-Medical Technology Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — BrightGene Bio-Medical Technology Co